NBE Therapeutics Overview

  • Founded
  • 2012
Founded
  • Status
  • Private
  • Employees
  • 27
Employees
  • Latest Deal Type
  • Series C
  • Latest Deal Amount
  • $22M
Latest Deal Amount
  • Investors
  • 5

NBE Therapeutics General Information

Description

Developer of a next-generation immune-stimulatory antibody-drug conjugate platform designed to improve the treatment options for cancer patients The company's platform creates highly potent and safe immune-stimulatory ADCs with an anthracycline payload, inducing a long-lasting immunological anti-tumor effect, enabling healthcare professionals to avail advanced drugs for more effective results.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
  • Technology Park Basel
  • Hochbergstrasse 60C
  • 4057 Basel
  • Switzerland
+41 061 000 00 00

NBE Therapeutics Timeline

2017201820192020
Financing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 2M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

NBE Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
8. Later Stage VC (Series C) 10-Jan-2020 $22M 000.00 Completed Generating Revenue
7. Later Stage VC (Series B) 28-Jun-2018 000.00 000.00 Completed Generating Revenue
6. Early Stage VC 01-Nov-2016 00.000 000.00 000.00 Completed Generating Revenue
5. Early Stage VC 11-Feb-2016 00.000 00.000 000.00 Completed Generating Revenue
4. Grant 05-Jan-2016 00.00 00.000 Completed Startup
3. Early Stage VC (Series A) 20-Feb-2015 00.000 00.000 00.00 Completed Startup
2. Grant 15-Mar-2014 $4.53M $2.76M Completed Startup
1. Seed Round 13-Dec-2013 $2.76M $2.76M Completed Startup
To view NBE Therapeutics’s complete valuation and funding history, request access »

NBE Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Preference 00,000 000.00 000.00 00 000.00 00.00
Preference 00,000 000.00 000.00 00 000.00 00.000
Preference 80,000 $6.91 $6.91 1x $6.91 25.79%
To view NBE Therapeutics’s complete cap table history, request access »

NBE Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of a next-generation immune-stimulatory antibody-drug conjugate platform designed to improve the treatment opt
Drug Discovery
Basel, Switzerland
27 As of 2019
000.00
00000000000 000.00

00000000

ure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur
0000000000000
Saint Louis, MO
0 As of 0000
00.000
00000 00000 00.000

00000000

t enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo cons
0000 000000000
Schlieren, Switzerland
0 As of 0000
000.00
00000000000 000.00
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

NBE Therapeutics Competitors (48)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Immunophotonics Venture Capital-Backed Saint Louis, MO 0 00.000 00000 00000 00.000
000000000 Venture Capital-Backed Schlieren, Switzerland 0 000.00 00000000000 000.00
000 0000000000000 Venture Capital-Backed Chester, United Kingdom 00 000.00 0000000000 0 000.00
000000 00000000000 Formerly VC-backed South San Francisco, CA 000 00000 000000 - 000 00000
0000000 Venture Capital-Backed San Diego, CA 00 00000 00000000000 00000
You’re viewing 5 of 48 competitors. Get the full list »

NBE Therapeutics Executive Team (6)

Name Title Board Seat Contact Info
Bertrand Damour Chief Executive Officer
Ulf Grawunder Ph.D Chief Operating Officer, Chief Development Officer & Board Member
Roger Beerli Ph.D Chief Scientific Officer
Wouter Verhoeven Chief Business Officer
Erich Schlick Chairman
You’re viewing 5 of 6 executive team members. Get the full list »

NBE Therapeutics Board Members (9)

Name Representing Role Since
Detlev Mennerich Ph.D Boehringer Ingelheim Venture Fund Board Member 000 0000
Erich Schlick NBE Therapeutics Chairman 000 0000
Hans-Peter Gerber Ph.D Self Board Member 000 0000
Jens Hennecke Ph.D Self Board Member 000 0000
Nanna Lüneborg Ph.D Novo Holdings Board Member 000 0000
You’re viewing 5 of 9 board members. Get the full list »

NBE Therapeutics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

NBE Therapeutics Investors (5)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Novo Holdings Venture Capital Minority 000 0000 000000 0
PPF Group PE/Buyout Minority 000 0000 000000 0
Swiss Federal Commission for Innovation and Technology Government 000 0000 000000 0
Venture Kick Accelerator/Incubator Minority 000 0000 000000 0
Boehringer Ingelheim Venture Fund Corporate Venture Capital Minority 000 0000 000000 0
To view NBE Therapeutics’s complete investors history, request access »